# A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

> **NCT07384975** · PHASE2 · RECRUITING · sponsor: **Navigator Medicines, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Hidradenitis Suppurativa (HS)

## Interventions

- **DRUG:** NAV-240
- **DRUG:** Placebo to match NAV-240

## Key facts

- **NCT ID:** NCT07384975
- **Lead sponsor:** Navigator Medicines, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-05
- **Primary completion:** 2027-09
- **Final completion:** 2027-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07384975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07384975, "A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07384975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*